Feed MRUS
MR

Merus

MRUS · NASDAQ

$90.00 +0.00% (+$0.00)
Market Cap $6.83B
P/E Ratio -
Div. Yield -
ROE 48.76%
Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 133.38x
P/B 10.32x
P/E N/A
Growth
80 /100
Growing
Rev. growth 11.85%
Book val. growth 23.46%
EPS growth N/A
Profitability
0 /100
Weak
Gross margin 217.50%
Net margin 654.44%
Op. margin 648.06%
Quality
1 /100
Poor
ROIC 48.81%
ROE 48.76%
ROA 43.38%
Debt
95 /100
Low
Debt/Equity 0.02x
Current ratio 7.97x
Net debt/EBITDA 0.94x
Stability
30 /100
Unstable
Beta 1.06x
Rev. volatility 50.15%
EPS volatility 55.37%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre MRUS
Online

Despre companie

Merus N.V. is a Dutch biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company is particularly known for its bispecific antibody technology, designed to selectively activate the immune system against cancer cells. Merus N.V. concentrates on developing treatments that can offer new hope to patients suffering from various types of cancer, including those who have failed other therapies.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Jan van de Winkel

Employees

260

Headquarters

Utrecht

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.